<p>Abcellera Biologics, Inc. ((ABCL)) 最近召开了第三季度财报电话会议。以下是会议的主要亮点。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
<p>AbCellera Biologics, Inc. 最近召开了财报电话会议，透露出乐观与挑战并存的局面。公司成功转型为临床阶段生物科技公司，展现出强劲的流动性。然而，净亏损和研发费用的增加，以及合作伙伴发起项目的停滞，呈现出财报电话会议中的复杂情绪。</p>
<h2>向临床阶段生物科技的转型</h2>
<p>AbCellera 通过启动 ABCL635 和 ABCL575 的 I 期临床试验，标志着从平台公司向临床阶段生物科技公司的重要里程碑。这两个项目均按计划推进，预示着公司临床工作的光明未来。</p>
<h2>强劲的流动性</h2>
<p>公司报告称流动性强劲，季度末可用资金约为 6.8 亿美元。其中包括 5.2 亿美元的现金及现金等价物和 1.6 亿美元的政府承诺资金，为未来的增长和发展提供了坚实的财务基础。</p>
<h2>新的临床制造设施</h2>
<p>AbCellera 已在其新的临床制造设施开始活动，标志着平台投资的重大完成。这一发展预计将增强公司的制造能力，并支持其临床阶段的运营。</p>
<h2>新任首席医学官的任命</h2>
<p>在一项战略举措中，AbCellera 任命 Dr. Sarah Noonberg 为新的首席医学官。Dr. Noonberg 在临床药物开发方面拥有超过 20 年的经验，其专业知识预计将推动公司的临床项目向前发展。</p>
<h2>收入增长</h2>
<p>公司报告季度收入增长至 900 万美元，较去年同期的 700 万美元有所上升。这一增长主要得益于来自合作项目的研究费用，反映出公司业务活动的扩展。</p>
<h2>净亏损增加</h2>
<p>AbCellera 本季度净亏损约为 5700 万美元，而去年同期为 5100 万美元。净亏损的增加突显了公司在投资增长和发展过程中面临的财务挑战。</p>
<h2>研发费用上升</h2>
<p>研发费用上升至 5500 万美元，比去年增加了 1400 万美元。这一增长凸显了 AbCellera 在内部和共同开发项目上的投资承诺，这对其向临床阶段公司的转型至关重要。</p>
<h2>合作伙伴发起项目的停滞</h2>
<p>自 2024 年以来，合作伙伴发起的临床项目数量保持不变，共启动了 103 个项目。这一停滞对公司在扩展其临床管道时构成挑战。</p>
<h2>前瞻性指导</h2>
<p>展望未来，AbCellera 计划在年底前将至少一个开发候选者推进至 IND 启动研究。公司仍专注于推进其主导项目 ABCL635 和 ABCL575 的 I 期试验。任命 Dr. Sarah Noonberg 为首席医学官预计将增强这些努力。</p>
<p>总之，AbCellera 的财报电话会议呈现了公司当前状况和未来前景的平衡视角。虽然向临床阶段生物科技的转型和强劲的流动性是积极的指标，但净亏损增加和合作伙伴发起项目的停滞等挑战依然存在。投资者将密切关注 AbCellera 在未来几个季度如何应对这些动态。</p>

ABCL

<p>AbCellera Biologics 举行了第三季度财报电话会议，强调其向临床阶段生物技术公司的转型，目前正在进行 ABCL635 和 ABCL575 的 I 期临床试验。公司报告了 6.8 亿美元的强劲流动性，但面临 5700 万美元的净亏损和 5500 万美元的研发费用上升的挑战。收入增加至 900 万美元，主要受研究费用推动。合作伙伴发起的项目停滞仍然是一个担忧。展望未来，AbCellera 计划将更多候选药物推进到 IND 申报前研究，新任首席医学官 Dr. Sarah Noonberg 预计将增强临床工作</p>

<p>Abcellera Biologics, Inc. ((ABCL)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Abcellera Biologics, Inc. ((ABCL)) 最近召开了第三季度财报电话会议。以下是会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
</div><p>AbCellera Biologics, Inc. recently held its earnings call, revealing a mix of optimism and challenges. The company successfully transitioned to a clinical-stage biotech, showcasing its strong liquidity position. However, increased net loss and R&amp;D expenses were noted, alongside a stagnation in partner-initiated programs, presenting a nuanced sentiment in the earnings call.</p>
<div class="lb-trans"><p>AbCellera Biologics, Inc. 最近召开了财报电话会议，透露出乐观与挑战并存的局面。公司成功转型为临床阶段生物科技公司，展现出强劲的流动性。然而，净亏损和研发费用的增加，以及合作伙伴发起项目的停滞，呈现出财报电话会议中的复杂情绪。</p>
</div><h2>Transition to Clinical-Stage Biotech</h2>
<div class="lb-trans"><h2>向临床阶段生物科技的转型</h2>
</div><p>AbCellera has marked a significant milestone by transitioning from a platform company to a clinical-stage biotech. This was achieved through the initiation of Phase I clinical trials for ABCL635 and ABCL575, both of which are progressing according to plan, indicating a promising future for the company’s clinical endeavors.</p>
<div class="lb-trans"><p>AbCellera 通过启动 ABCL635 和 ABCL575 的 I 期临床试验，标志着从平台公司向临床阶段生物科技公司的重要里程碑。这两个项目均按计划推进，预示着公司临床工作的光明未来。</p>
</div><h2>Strong Liquidity Position</h2>
<div class="lb-trans"><h2>强劲的流动性</h2>
</div><p>The company reported a robust liquidity position, ending the quarter with approximately $680 million available. This includes $520 million in cash and cash equivalents and $160 million in committed government funding, providing a solid financial foundation for future growth and development.</p>
<div class="lb-trans"><p>公司报告称流动性强劲，季度末可用资金约为 6.8 亿美元。其中包括 5.2 亿美元的现金及现金等价物和 1.6 亿美元的政府承诺资金，为未来的增长和发展提供了坚实的财务基础。</p>
</div><h2>New Clinical Manufacturing Facility</h2>
<div class="lb-trans"><h2>新的临床制造设施</h2>
</div><p>AbCellera has commenced activities at its new clinical manufacturing facility, marking a substantial completion of platform investments. This development is expected to enhance the company’s manufacturing capabilities and support its clinical-stage operations.</p>
<div class="lb-trans"><p>AbCellera 已在其新的临床制造设施开始活动，标志着平台投资的重大完成。这一发展预计将增强公司的制造能力，并支持其临床阶段的运营。</p>
</div><h2>Appointment of New Chief Medical Officer</h2>
<div class="lb-trans"><h2>新任首席医学官的任命</h2>
</div><p>In a strategic move, AbCellera appointed Dr. Sarah Noonberg as the new Chief Medical Officer. With over 20 years of experience in clinical drug development, Dr. Noonberg’s expertise is anticipated to drive the company’s clinical programs forward.</p>
<div class="lb-trans"><p>在一项战略举措中，AbCellera 任命 Dr. Sarah Noonberg 为新的首席医学官。Dr. Noonberg 在临床药物开发方面拥有超过 20 年的经验，其专业知识预计将推动公司的临床项目向前发展。</p>
</div><h2>Increase in Revenue</h2>
<div class="lb-trans"><h2>收入增长</h2>
</div><p>The company reported a revenue increase to $9 million for the quarter, up from $7 million in the same period last year. This growth was primarily driven by research fees from partnered programs, reflecting the company’s expanding business activities.</p>
<div class="lb-trans"><p>公司报告季度收入增长至 900 万美元，较去年同期的 700 万美元有所上升。这一增长主要得益于来自合作项目的研究费用，反映出公司业务活动的扩展。</p>
</div><h2>Increased Net Loss</h2>
<div class="lb-trans"><h2>净亏损增加</h2>
</div><p>AbCellera experienced a net loss of approximately $57 million for the quarter, compared to $51 million in the previous year. This increase in net loss highlights the financial challenges the company faces as it invests in its growth and development.</p>
<div class="lb-trans"><p>AbCellera 本季度净亏损约为 5700 万美元，而去年同期为 5100 万美元。净亏损的增加突显了公司在投资增长和发展过程中面临的财务挑战。</p>
</div><h2>Rise in Research and Development Expenses</h2>
<div class="lb-trans"><h2>研发费用上升</h2>
</div><p>Research and development expenses rose to $55 million, an increase of $14 million from the previous year. This rise underscores AbCellera’s commitment to investing in internal and co-development programs, crucial for its transition to a clinical-stage company.</p>
<div class="lb-trans"><p>研发费用上升至 5500 万美元，比去年增加了 1400 万美元。这一增长凸显了 AbCellera 在内部和共同开发项目上的投资承诺，这对其向临床阶段公司的转型至关重要。</p>
</div><h2>Stagnation in Partner-Initiated Programs</h2>
<div class="lb-trans"><h2>合作伙伴发起项目的停滞</h2>
</div><p>The number of partner-initiated programs in the clinic has remained stagnant since 2024, with a total of 103 programs initiated. This stagnation poses a challenge for the company as it seeks to expand its clinical pipeline.</p>
<div class="lb-trans"><p>自 2024 年以来，合作伙伴发起的临床项目数量保持不变，共启动了 103 个项目。这一停滞对公司在扩展其临床管道时构成挑战。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Looking ahead, AbCellera aims to advance at least one more development candidate into IND-enabling studies by year-end. The company remains focused on progressing its lead programs, ABCL635 and ABCL575, through Phase I trials. The appointment of Dr. Sarah Noonberg as Chief Medical Officer is expected to bolster these efforts.</p>
<div class="lb-trans"><p>展望未来，AbCellera 计划在年底前将至少一个开发候选者推进至 IND 启动研究。公司仍专注于推进其主导项目 ABCL635 和 ABCL575 的 I 期试验。任命 Dr. Sarah Noonberg 为首席医学官预计将增强这些努力。</p>
</div><p>In conclusion, AbCellera’s earnings call presented a balanced view of the company’s current position and future prospects. While the transition to a clinical-stage biotech and strong liquidity are positive indicators, challenges such as increased net loss and stagnant partner-initiated programs remain. Investors will be keenly watching how AbCellera navigates these dynamics in the coming quarters.</p>
<div class="lb-trans"><p>总之，AbCellera 的财报电话会议呈现了公司当前状况和未来前景的平衡视角。虽然向临床阶段生物科技的转型和强劲的流动性是积极的指标，但净亏损增加和合作伙伴发起项目的停滞等挑战依然存在。投资者将密切关注 AbCellera 在未来几个季度如何应对这些动态。</p>
</div>

Abcellera Biologics 的财报电话会议：主要见解